146 related articles for article (PubMed ID: 17547692)
21. Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity.
Hosking LK; Boyd PR; Xu CF; Nissum M; Cantone K; Purvis IJ; Khakhar R; Barnes MR; Liberwirth U; Hagen-Mann K; Ehm MG; Riley JH
Pharmacogenomics J; 2002; 2(3):165-75. PubMed ID: 12082588
[TBL] [Abstract][Full Text] [Related]
22. Study design and genetic susceptibility factors in the risk assessment of chemical carcinogens.
Caporaso N
Ann Ist Super Sanita; 1991; 27(4):621-30. PubMed ID: 1820735
[TBL] [Abstract][Full Text] [Related]
23. Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension.
Zateyshchikov DA; Minushkina LO; Brovkin AN; Savel'eva EG; Zateyshchikova AA; Manchaeva BB; Nikitin AG; Sidorenko BA; Nosikov VV
Fundam Clin Pharmacol; 2007 Aug; 21(4):437-43. PubMed ID: 17635183
[TBL] [Abstract][Full Text] [Related]
24. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.
Crescenti A; Mas S; Gassó P; Parellada E; Bernardo M; Lafuente A
Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):807-11. PubMed ID: 18346175
[TBL] [Abstract][Full Text] [Related]
25. L-myc gene polymorphism and risk of thyroid cancer.
Yaylim-Eraltan I; Bozkurt N; Ergen A; Zeybek U; Ozturk O; Arikan S; Erbil Y; Uslu I; Camlica H; Isbir T
Exp Oncol; 2008 Jun; 30(2):117-20. PubMed ID: 18566574
[TBL] [Abstract][Full Text] [Related]
26. Different genotype distribution of the GNB3 C825T polymorphism of the G protein beta3 subunit in adenomas and differentiated thyroid carcinomas of follicular cell origin.
Sheu SY; Görges R; Ensinger C; Ofner D; Farid NR; Siffert W; Schmid KW
J Pathol; 2005 Dec; 207(4):430-5. PubMed ID: 16178055
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 polymorphism and the presence of anti-LKM-1 in patients with chronic hepatitis C.
Hijikata M; Miyakawa H; Matsushita M; Kako M; Ohta Y; Mishiro S
Biochem Biophys Res Commun; 2000 Apr; 270(3):922-6. PubMed ID: 10772926
[TBL] [Abstract][Full Text] [Related]
28. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and cancer risk: the Croatian case-control study.
Reljic A; Simundic AM; Topic E; Nikolac N; Justinic D; Stefanovic M
Clin Biochem; 2007 Sep; 40(13-14):981-5. PubMed ID: 17573062
[TBL] [Abstract][Full Text] [Related]
29. [Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].
Grzesiak M; Beszłej A; Lebioda A; Jonkisz A; Dobosz T; Kiejna A
Psychiatr Pol; 2003; 37(3):433-44. PubMed ID: 13677973
[TBL] [Abstract][Full Text] [Related]
30. The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.
Casner PR
J Clin Pharmacol; 2005 Nov; 45(11):1230-5. PubMed ID: 16239355
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of metabolic enzymes CYP1A1, CYP2D6, GSTM1 and GSTT1 and leukemia susceptibility.
Chen HC; Hu WX; Liu QX; Li WK; Chen FZ; Rao ZZ; Liu XF; Luo YP; Cao YF
Eur J Cancer Prev; 2008 Jun; 17(3):251-8. PubMed ID: 18414197
[TBL] [Abstract][Full Text] [Related]
32. Genetic variation in D7S1875 repeat polymorphism of leptin gene is associated with increased risk for depression: a case-control study from India.
Kapoor M; Kapur S; Mehra S; Dube U; Sharad S; Sidhu S
Depress Anxiety; 2009; 26(9):791-5. PubMed ID: 19382181
[TBL] [Abstract][Full Text] [Related]
33. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
34. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
Naidu R; Har YC; Taib NA
J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
[TBL] [Abstract][Full Text] [Related]
35. Association of polymorphic G1934A variant (allele *4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women.
Levkovich NN; Gorovenko NG; Myasoedov DV
Exp Oncol; 2011 Sep; 33(3):136-9. PubMed ID: 21956465
[TBL] [Abstract][Full Text] [Related]
36. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias.
Lemos MC; Cabrita FJ; Silva HA; Vivan M; Plácido F; Regateiro FJ
Carcinogenesis; 1999 Jul; 20(7):1225-9. PubMed ID: 10383893
[TBL] [Abstract][Full Text] [Related]
38. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India.
Srivastava DS; Mandhani A; Mittal RD
Arch Toxicol; 2008 Sep; 82(9):633-9. PubMed ID: 18200441
[TBL] [Abstract][Full Text] [Related]
40. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.
Otani K; Ujike H; Sakai A; Okahisa Y; Kotaka T; Inada T; Harano M; Komiyama T; Hori T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
Neurosci Lett; 2008 Mar; 434(1):88-92. PubMed ID: 18280655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
